BIO-Europe Spring® 2016: QureTech Bio explains novel approach to antibiotic development

April 28, 2016
Dr. Fritiof Pontén, CEO of QureTech Bio—one of Sweden's youngest biotech companies—talks with Mike Ward, global director of content for Informa Pharma Intelligence's insights portfolio, about QureTech's business foundation, its novel technology for disabling bacteria and how the company's products could be a solution to the global challenge of antibiotic resistance. QureTech is developing a new class of antibacterial agents that may have broad-spectrum activity against Chlamydia and other pathogens. Termed virulence blockers, these agents selectively disarm the pathogenic capability of certain bacteria, without affecting normal bacterial flora, decreasing the selection pressure for resistance development.
Previous Video
BIO-Europe Spring® 2016: New VC bioqube on open innovation roots and investments targets
BIO-Europe Spring® 2016: New VC bioqube on open innovation roots and investments targets

Nico Vandervelpen, managing partner and co-founder of bioqube ventures—a Johnson & Johnson-partnered ventur...

Next Video
BIO-Europe Spring® 2016: CEVEC CEO talks US deals to expand business
BIO-Europe Spring® 2016: CEVEC CEO talks US deals to expand business

Frank Ubags, CEO of CEVEC—a company offering industrial scale production of viral vectors for gene therapy ...